ETAS®Study Results
Heat Shock Protein (HSP)
Functions of HSP70
RESEARCHInducing effect of HSP70 expression in organs
ETAS® increased HSP70 expression in the stomach, liver and kidneys.
Not only physical stressors like heat and UV rays but also mental stressors like tension and anxiety give damage to the body. Heat shock proteins (HSP) are proteins that work to repair or refold proteins damaged by such stressors.
ETAS® administration on sleep-deprived mice*1 increased HSP70 expression in their stomach, liver and kidneys. The results suggested that ETAS® could reduce physical load caused by stress.
Tomohiro Ito et al., Journal of Food Science, 79(3): 413-419 (2014)
Non-clinical study (in vivo)
Animal: 6-week-old male ddY/SPF mice
Groups: Control (n=8), sleep-deprivation (n=8), sleep-deprivation/low-dose ETAS® (n=8)
, and sleep-deprivation/high-dose ETAS® (n=8)
Doses and period: ETAS®50 400 and 2,000 mg/kg/day for 7days and then for 3 days with 12-hour sleep-deprivation stress
Evaluation: HSP70 expression levels in the stomach, liver, and kidney, and blood corticosterone and lipid peroxide (LPO) concentrations in addition to observations of body weight and hair loss
Results
ETAS® elevated HSP70 expression levels in the stomach, liver, and kidney and lowered blood corticosterone and lipid peroxide concentrations. Furthermore, ETAS® improved body weight reduction and hair loss.
*1 Sleep-deprived mice: model mice with sleep deprivation induced by adding stress or stimuli to disturb their sleep-onset. They have been widely used to see the effects of sleep loss on cognitive function.
RESEARCHInducing effect of HSP70 expression in human body
ETAS® increased HSP70 expression in healthy adults.
ETAS® intake significantly increased HSP70 expression in the white blood cells in healthy adults. ETAS® could help maintain normal body functions by inducing HSP70 expression without external stimulations.
Tomohiro Ito et al., Journal of Food Science, 79(3): 413-419 (2014)
Clinical study
Design: A randomized, open-label trial
Subject: 20 healthy male volunteers
Groups: Low-dose (n=10), middle-dose (n=5), and high-dose ETAS® (n=5)
Doses and period: ETAS®50 150, 200, and 300 mg/day for 7 days
Endpoint: Blood HSP70 mRNA expression level
Result
Intake of ETAS®50 over 200 mg/day increased HSP70 expression levels.
